Pfizer Fires Shot Across RSV Bow With Topline Data In Younger Adults
The drug maker previously said approval in adults 18-59 could drive some evolution in a space where 60 mostly remains the lower limit for recommended use of RSV vaccines.
The drug maker previously said approval in adults 18-59 could drive some evolution in a space where 60 mostly remains the lower limit for recommended use of RSV vaccines.